Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT00371488 Completed - Neoplasms, Breast Clinical Trials

GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

Start date: April 6, 2006
Phase: Phase 1
Study type: Interventional

This is two-part study (Phase I/Phase II). Part I is designed to find the optimal (best) doses of GW572016 and trastuzumab when given together,Part II is designed to evaluate the tumor response rate (shrinkage or lack of growth) in patients receiving lapatinib and trastuzumab.

NCT ID: NCT00371345 Completed - Breast Cancer Clinical Trials

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Start date: December 2006
Phase: Phase 2
Study type: Interventional

This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer

NCT ID: NCT00371254 Completed - Breast Cancer Clinical Trials

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Start date: December 2006
Phase: Phase 2
Study type: Interventional

This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.

NCT ID: NCT00370552 Completed - Clinical trials for Metastatic Breast Cancer

A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer

Start date: March 2007
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast cancer. The study will also assess the safety of this combination treatment.

NCT ID: NCT00370240 Completed - Breast Neoplasms Clinical Trials

Chlorhydrate of Ropivacaine and Breast Cancer Surgery

Start date: September 2006
Phase: Phase 4
Study type: Interventional

The aim of the study is to evaluate the effect of local anesthetic (chlorhydrate of ropivacaine) to prevent chronic pain after breast surgery for cancer.

NCT ID: NCT00369850 Completed - Breast Cancer Clinical Trials

Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98

Start date: May 2004
Phase: Phase 3
Study type: Interventional

RATIONALE: Diagnostic procedures, such as bone mineral density testing and x-ray, help measure bone loss in women receiving treatment for breast cancer. The test results may help doctors plan better treatment. PURPOSE: This phase III trial is studying bone density and bone loss in postmenopausal women with breast cancer receiving treatment in clinical trial IBCSG-1-98.

NCT ID: NCT00369655 Completed - Clinical trials for Metastatic Breast Cancer

VEGF Trap in Treating Patients With Metastatic Breast Cancer

Start date: January 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well VEGF Trap works in treating patients with metastatic breast cancer. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor

NCT ID: NCT00368875 Completed - Clinical trials for Stage IV Breast Cancer

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

Start date: July 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of vorinostat when given together with paclitaxel and bevacizumab and to see how well they work in treating patients with metastatic breast cancer and/or breast cancer that has recurred in the chest wall and cannot be removed by surgery. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving vorinostat together with paclitaxel and bevacizumab may kill more tumor cells.

NCT ID: NCT00367471 Completed - Neoplasms, Breast Clinical Trials

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

Start date: December 7, 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the optimally-tolerated regimens (OTR) for lapatinib in combination with paclitaxel, carboplatin with and without trastuzumab in patients with metastatic breast cancer.

NCT ID: NCT00365599 Completed - Breast Cancer Clinical Trials

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

Start date: February 2006
Phase: Phase 2
Study type: Interventional

Phase II trial to explore the efficacy of vorinostat and tamoxifen combined.